Trial Profile
Randomised, Double-blind, Placebo-controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Multiple Rising Oral Doses of BI 685509 Over 28 Days in Male and Female Patients With Diabetic Nephropathy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Avenciguat (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 20 Dec 2019 Status changed from recruiting to completed.
- 26 Nov 2019 Planned End Date changed from 10 Dec 2020 to 10 Dec 2019.
- 26 Nov 2019 Planned primary completion date changed from 10 Dec 2020 to 10 Dec 2019.